MarketPeel
Insider Trading Intelligence
RH

Robert D. Hardie

ABOS
10% OWNER · ACUMEN PHARMACEUTICALS, INC. · CIK 0001804350
FILING MIX · LIFETIME55%/45%
BUYS
6
SELLS
5
TOTAL VALUE
$17.00M
COMPANIES
1
ACTIVE SINCE
Jul 2021
HOLDINGS NOW
0
AVG SELL PX
TRADE KIND
SHOWING 11 / 11
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Robert D. Hardie, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%-6.24%+0.62%-6.85%-6.85%
14d2+0.00%-8.37%-0.43%-7.93%-7.93%
30d2+0.00%-25.79%+2.04%-27.83%-27.83%
60d2+0.00%-22.82%+4.65%-27.48%-27.48%
90d2+0.00%-25.00%-0.67%-24.33%-24.33%
180d2+0.00%-66.68%+11.09%-77.77%-77.77%
1y2+0.00%-72.77%-10.21%-62.56%-62.56%
2y2+0.00%-75.00%+4.69%-79.69%-79.69%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABOS · 0 shares · as of Jul 6, 2021
0987,7891,975,5782,963,3673,951,156SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
FLOW · 6 buys / 5 sellsCOVERAGE · 1 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
750,000$16.00$12.00M3,951,156Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
2,076,3263,201,156Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
2,076,3260Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
1,124,8301,124,830Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
1,124,8300Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
657,985657,985Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
312,500$16.00$5.00M3,352,693Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
2,950,4843,040,193Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
1,315,9690Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
1,634,5150Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
657,9850Jul 6, 2021Jul 8, 2021View →
Other insiders · ABOS
Loading peer insiders…
About this filer
CIK 0001804350
ROLE
10% Owner
PRIMARY
ABOS
COMPANIES
1
ACTIVE SINCE
Jul 2021
MARKETPEEL · /INSIDER/0001804350DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback